We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is DexCom (DXCM) Stock Outpacing Its Medical Peers This Year?
Read MoreHide Full Article
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has DexCom (DXCM - Free Report) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
DexCom is a member of the Medical sector. This group includes 1088 individual stocks and currently holds a Zacks Sector Rank of #3. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. DexCom is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for DXCM's full-year earnings has moved 16.8% higher within the past quarter. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Our latest available data shows that DXCM has returned about 8% since the start of the calendar year. In comparison, Medical companies have returned an average of -4%. As we can see, DexCom is performing better than its sector in the calendar year.
Exscientia PLC Sponsored ADR (EXAI - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 8.1%.
The consensus estimate for Exscientia PLC Sponsored ADR's current year EPS has increased 3.8% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, DexCom belongs to the Medical - Instruments industry, which includes 93 individual stocks and currently sits at #71 in the Zacks Industry Rank. This group has gained an average of 1.6% so far this year, so DXCM is performing better in this area.
On the other hand, Exscientia PLC Sponsored ADR belongs to the Medical - Drugs industry. This 194-stock industry is currently ranked #71. The industry has moved -3.2% year to date.
Investors with an interest in Medical stocks should continue to track DexCom and Exscientia PLC Sponsored ADR. These stocks will be looking to continue their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is DexCom (DXCM) Stock Outpacing Its Medical Peers This Year?
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has DexCom (DXCM - Free Report) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
DexCom is a member of the Medical sector. This group includes 1088 individual stocks and currently holds a Zacks Sector Rank of #3. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. DexCom is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for DXCM's full-year earnings has moved 16.8% higher within the past quarter. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Our latest available data shows that DXCM has returned about 8% since the start of the calendar year. In comparison, Medical companies have returned an average of -4%. As we can see, DexCom is performing better than its sector in the calendar year.
Exscientia PLC Sponsored ADR (EXAI - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 8.1%.
The consensus estimate for Exscientia PLC Sponsored ADR's current year EPS has increased 3.8% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, DexCom belongs to the Medical - Instruments industry, which includes 93 individual stocks and currently sits at #71 in the Zacks Industry Rank. This group has gained an average of 1.6% so far this year, so DXCM is performing better in this area.
On the other hand, Exscientia PLC Sponsored ADR belongs to the Medical - Drugs industry. This 194-stock industry is currently ranked #71. The industry has moved -3.2% year to date.
Investors with an interest in Medical stocks should continue to track DexCom and Exscientia PLC Sponsored ADR. These stocks will be looking to continue their solid performance.